ReviewMedical science monitor : international medical journal of experimental and clinical research2024
Biomarkers for Early Prediction and Management of Preeclampsia: A Comprehensive Review.
Review in Medical science monitor : international medical journal of experimental and clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Towards the Development of a Conceptual Framework of the Determinants of Pre-Eclampsia: A Hierarchical Systematic Review of Biomarkers.BJOG : an international journal of obstetrics and gynaecology · 2026Pooled it
- Review
- The Immuno-Cardiovascular Storm of Pre-Eclampsia: Cytokine-Mediated Endothelial Injury, Thrombosis, and Maternal Cardiovascular Instability.Comprehensive Physiology · 2026Review
- Serum biochemical and inflammatory biomarker profiles in severe preeclampsia and their clinical predictive value.Journal of medical biochemistry · 2026Article
- Cross-species insights into placental evolution and diseases at the single-cell resolution.Nature communications · 2026Article
- Development of a Triage Tool for Stratification and Referral of Women at Risk of Preeclampsia in Low-Resource Antenatal Settings: A Prospective Cohort Study.Health science reports · 2026Article
- NT-proBNP as a Predictive and Prognostic Biomarker for Complications in Hypertensive Pregnancy Disorders.Journal of clinical medicine · 2026Article
- Hypertensive Pregnancy Disorders: From Mechanisms to Management.American journal of hypertension · 2026Review
- Integrative Transcriptomic and Network Pharmacology Analysis Suggests Potential Mechanisms of Propofol in Early-Onset Preeclampsia.International journal of women's health · 2026Article
- The Thrombopoietic Signature of Preeclampsia: Diagnostic and Monitoring Insights from the Immature Platelet Fraction.Diagnostics (Basel, Switzerland) · 2025Article
- Adverse Materno-Foetal Outcomes of Pre-Eclampsia at a Rural Tertiary Hospital in the Eastern Cape Province of South Africa.International journal of environmental research and public health · 2025Article
- First-trimester pan-immune-inflammation value predicts preeclampsia in a dose-dependent linear pattern.BMC pregnancy and childbirth · 2025Article
- The Prognostic Value and Perioperative Dynamics of the HALP Score in Placenta Accreta Spectrum Surgeries.Journal of clinical medicine · 2025Article
- The Role of Angiogenetic Factors in Preeclampsia.International journal of molecular sciences · 2025Review
- Evaluation of oxidative stress markers and the angiogenic factors in preeclampsia and associated features.BMC pregnancy and childbirth · 2025Article
- Adipokines in preeclampsia: disrupted signaling pathways and novel therapeutic strategies.European journal of medical research · 2025Review
- Combined assessment of placental growth factor, uterine artery pulsation index, and mean arterial pressure for predicting preeclampsia.American journal of translational research · 2025Article
- Prediction of late-onset preeclampsia using plasma proteomics: a longitudinal multi-cohort study.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia is a common complication of pregnancy. It is a multi-organ disorder that remains one of the main causes of maternal morbidity and mortality. Additionally, preeclampsia leads to many complications that can occur in the fetus or newborn. Preeclampsia occurs in about 1 in 20 pregnant women. This review focuses on the prediction of preeclampsia in women, using various biomarkers, in particular, a factor combining the use of soluble FMS-like tyrosinokinase-1 (sFlt-1) and placental growth factor (PlGF). A low value of the sFlt-1/PlGF ratio rules out the occurrence of preeclampsia within 4 weeks of the test result, and its high value predicts the occurrence of preeclampsia within even 1 week. The review also highlights other factors, such as pregnancy-associated plasma protein A, placental protein 13, disintegrin and metalloprotease 12, ß-human chorionic gonadotropin, inhibin-A, soluble endoglin, nitric oxide, and growth differentiation factor 15. Biomarker testing offers reliable and cost-effective screening methods for early detection, prognosis, and monitoring of preeclampsia. Early diagnosis in groups of women at high risk for preeclampsia allows for quick intervention, preventing the undesirable effects of preeclampsia. However, further research is needed to validate and optimize the use of biomarkers for more accurate prediction and diagnosis. This article aims to review the role of biomarkers, including the sFlt1/PlGF ratio, in the prognosis and management of preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.